Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyCareFirst Therapeutic Apheresis Coverage Update | …
    Ask Trek AI about this page
    RetiredCareFirstPolicy 7.01.030

    Therapeutic Apheresis

    Customize your policy alerts

    Sign up for CareFirst Policy 7.01.030 alerts

    Get alerted when Policy 7.01.030 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity indications and experimental/investigational exclusions for therapeutic apheresis procedures; CareFirst adopts MCG Care Guidelines® for clinical criteria and requires checking member contract and prior authorization when applicable.

    Policy Summary
    PayerCareFirst
    PolicyTherapeutic Apheresis
    Policy CodePolicy 7.01.030
    Change TypeRetiredadopted MCG criteria
    Effective Date02/01/2026
    Last ReviewOct 8, 2025
    Next Review DateN/A
    Key ActionSubmit preauthorization requests when specified by contract and verify member benefits; reviewers will reference MCG Care Guidelines® for medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    Update 2025: CareFirst adopted the position of MCG Care Guidelines® and retired the policy; literature review March 2025–October 2025 did not change conclusions.

    Update 2024: MCG updates resulted in adding age-related macular degeneration and Refsum's disease as medically necessary indications and classifying other diagnoses as experimental/investigational.

    Multiple prior updates (2019, 2017, 2015, 2013, 2010, 2008) modified or clarified medically necessary indications over time (examples: addition of NMDA receptor antibody encephalitis in 2019; ABO incompatible HPC transplantation and ANCA vasculitis in 2010).

    ~60Listed Medically Necessary Indications
    MCGAdopted External Criteria Source

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1
    Policy Status

    Coverage Summary

    Scope: Defines medically necessary indications and experimental/investigational exclusions for therapeutic apheresis (plasmapheresis, plasma exchange, cytapheresis, extracorporeal immunoadsorption) and requires checking member contract and prior authorization when applicable.

    Coverage stance and status: CareFirst's stance is mixed (some indications are medically necessary; others are experimental/investigational). The policy is RETIRED and effective 02/01/2026; CareFirst has adopted the proprietary clinical criteria of MCG Care Guidelines® for medical necessity and clinical appropriateness.

    High-level note: The policy references ~60 listed medically necessary indications and indicates adoption of external criteria from MCG (see provider guidance to use MCG criteria). Statistical/summary items in the brief (e.g., counts and adopted source) are noted here but not duplicated in the stats bar.

    Policy Key Values
    policy_number7.01.030
    subjectTherapeutic Apheresis
    statusRETIRED
    effective_date02/01/2026
    last_review10/08/2025
    adopted_criteria_sourceCareFirst adopted MCG Care Guidelines® (Therapeutic Apheresis) for medical necessity guidance (2025).
    serum_creatinine_threshold> 5.8 mg/dl (for ANCA-associated vasculitis with associated renal failure)

    Medically Necessary Indications

    Medically Necessary Indications

    Therapeutic apheresis is considered medically necessary for any of the conditions listed below:

    ABO incompatible hematopoietic progenitor cell transplantation
    acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome); severity grade 1-2 within 2 weeks of onset; severity grade 3-5 within 4 weeks of onset; as an alternative to intravenous immunoglobulin (IVIG)
    age-related macular degeneration
    amanita mushroom poisoning
    ANCA-associated vasculitis with associated renal failure (serum Cr > 5.8 mg/dl)> 5.8 mg/dl

    Experimental / Investigational Indications

    Experimental/Investigational Indications

    All other applications of therapeutic apheresis for conditions not listed in the medically necessary statement are considered experimental/investigational because they do not meet TEC criteria #2-5.

    Indications lacking sufficient evidence include (but are not limited to): ALS, asthma, chronic fatigue syndrome (including Long COVID), paraneoplastic syndromes including Lambert-Eaton myasthenic syndrome, paraproteinemic peripheral neuropathy associated with POEMS syndrome and MGUS, pemphigus, polymyositis, dermatomyositis, scleroderma, systemic lupus erythematosus (SLE), Crohn's disease (except limited evidence for ulcerative colitis with GMA), and other diagnoses not listed as medically necessary.
    The policy applies BlueCross BlueShield Association (BCBSA) Medical Policy Services (MPS)/TEC assessment criteria: all five criteria must be met for procedures to be considered non-experimental.

    BCBSA/MPS (TEC) five criteria are listed in policy

    See the Definitions entry for Experimental/Investigational for the formal description and the five BCBSA/MPS TEC criteria that must all be met for a technology to avoid that classification.

    Implications: Therapeutic apheresis indications that are not included in the medically necessary list are considered experimental/investigational because they do not meet TEC criteria #2–5 and may be denied for not meeting policy criteria; providers should submit preauthorization requests and verify member contract benefits when applicable.

    Provider Actions & Documentation

    Prior Authorization

    Prior Authorization Required When Specified By Contract

    Some services, devices, drugs, and places of service require prior authorization; providers should submit preauthorization requests online or call 1-866-773-2884 (1-866-PRE-AUTH). Always check the member's contract for benefits.

    • Call 1-866-773-2884 (1-866-PRE-AUTH) for prior authorization
    • Always check the member's contract for benefits
    Documentation Required

    Use of MCG Criteria

    CareFirst has adopted MCG Care Guidelines® (Therapeutic Apheresis) for medical necessity and clinical appropriateness; reviewers will reference those proprietary criteria.

    Background & Evidence

    Background: Therapeutic apheresis encompasses procedures that separate plasma or cellular blood components for treatment, including plasmapheresis, plasma exchange, cytapheresis, and extracorporeal immunoadsorption. Plasmapheresis/plasma exchange remove plasma which may be treated, returned, or replaced; cytapheresis selectively removes cellular elements (erythrocytapheresis, leukapheresis, thrombocytapheresis). Extracorporeal immunoadsorption uses filters (for example, Protein A columns) to selectively remove plasma components and return treated plasma to the patient.

    Regulatory and guidance references: The FDA has approved specific LDL apheresis systems (Liposorber LA-15® and HELP®) and granted humanitarian device pathways and approvals for additional indications; the FDA also issued Emergency Use Authorizations during COVID-19 for Spectra Optia and Depuro D2000 adsorption cartridges. CareFirst references guidance from the American Society for Apheresis and has adopted MCG Care Guidelines® for medical necessity and clinical appropriateness.

    Evidence note: A literature review covering March 2025–October 2025 found no change in conclusions; CareFirst's 2025 update states adoption of MCG criteria and that recent literature does not change prior conclusions regarding therapeutic apheresis. Prior evidence summaries note limited or weak data for many experimental/investigational indications and cite observational studies, case series, single-arm trials, and the need for robust randomized controlled trials and systematic reviews.

    Evidence Items
    MCG AdoptionCareFirst adopted MCG Care Guidelines® (Therapeutic Apheresis) for medical necessity and clinical appropriateness; reviewers will reference MCG proprietary criteria.

    Revision History

    2025retirement/adoptionLatest

    Policy retired; CareFirst adopted MCG Care Guidelines® (Therapeutic Apheresis) and proprietary clinical criteria for medical necessity; literature search March–October 2025 found no change in conclusions.

    2024revised indications

    MCG updates resulted in adding age-related macular degeneration and Refsum's disease as medically necessary indications and updating the experimental/investigational statement to include all other diagnoses not listed as medically necessary.

    historical (2019, 2017, 2015, 2013, 2010, 2008)
    Policy Summary
    PayerCareFirst
    PolicyTherapeutic Apheresis
    Policy CodePolicy 7.01.030
    Change TypeRetiredadopted MCG criteria
    Effective Date02/01/2026
    Last ReviewOct 8, 2025
    Next Review DateN/A
    Key ActionSubmit preauthorization requests when specified by contract and verify member benefits; reviewers will reference MCG Care Guidelines® for medical necessity.
    SourceLink
    On This Page
    Coverage SummaryMedically Necessary IndicationsExperimental / Investigational IndicationsProvider Actions & DocumentationBackground & EvidenceRevision History

    Serum creatinine threshold per policy

    anti-glomerular basement membrane disease (progressive renal failure due to anti-basement membrane antibodies) (Goodpasture's syndrome)
    antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    antiphospholipid syndrome (catastrophic)
    autoimmune encephalitis
    babesiosis (severe)
    cardiac transplant
    chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    cryoglobulinemia
    cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) for stage III or stage IV disease
    familial homozygous hypercholesterolemia
    focal segmental glomerulosclerosis
    graft vs host disease, steroid-dependent or steroid-refractory
    HELLP syndrome of pregnancy (hemolysis, elevated liver enzymes, low platelets)
    hemochromatosis (hereditary)
    hemolytic uremic syndrome (HUS)
    heterozygous familial hypercholesterolemia
    homozygous familial hypercholesterolemia
    hyperviscosity due to clonal thrombocytosis (e.g., essential thrombocythemia or other myeloproliferative disorder)
    hyperviscosity due to erythrocytosis
    hyperviscosity due to leukocytosis
    hyperviscosity due to monoclonal gammopathy (e.g., Waldenstrom macroglobulinemia; multiple myeloma with IgA, IgG, or kappa light chains)
    idiopathic thrombocytopenic purpura (ITP) in life-threatening situations
    leukemia
    lipoprotein(a) hyperlipoproteinemia
    liver failure (acute)
    liver transplant (ABO-incompatible)
    lung allograft rejection
    multiple sclerosis (acute, unresponsive to steroids) or other conditions such as transverse myelitis, acute fulminant CNS demyelination
    myasthenia gravis
    neuromyelitis optica spectrum disorder (acute), when high-dose intravenous steroids fail to resolve symptoms
    N-methyl-D-aspartate receptor antibody encephalitis
    paraproteinemia polyneuropathy, IgA, or IgG
    pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)
    phytanic acid storage disease (Refsum disease)
    polyarteritis nodosa associated with hepatitis B virus, in combination with glucocorticoids
    polyneuropathy due to monoclonal gammopathy (paraprotein neuropathy) with IgA, IgG, or IgM
    post-transfusion purpura
    pure red cell aplasia unresponsive to steroid and immunosuppressive therapy (including sickle cell disease/sickle cell anemia)
    Refsum's disease
    renal transplant (ABO-compatible)
    renal transplant (ABO-incompatible)
    sickle cell disease (acute) with complications
    sickle cell disease (nonacute) with complications
    rheumatoid arthritis
    solid organ transplant patients in acute antibody-mediated organ rejection or in those at high risk for antibody-mediated organ rejection
    thrombotic microangiopathy (drug-related)
    thrombotic thrombocytopenic purpura (TTP)
    vasculitis associated with Human Immunodeficiency Virus (HIV)
    Wilson disease
    Denial Risk

    Experimental/Investigational Denial Risk

    Therapeutic apheresis for indications not listed as medically necessary is considered experimental/investigational and may be denied as not meeting policy criteria.

    Literature Review 2025
    Search March 2025–October 2025 found no change in conclusions; policy retired.

    Experimental/Investigational: Services or supplies that do not meet the five BCBSA/MPS assessment criteria (final U.S. regulatory approval, evidence permitting conclusions about health outcomes, demonstrated net health outcome improvement, parity with established alternatives, and attainability outside investigational settings) are considered experimental/investigational.

    historical updates

    Multiple prior updates modified or clarified medically necessary indications over time (examples: addition of N-methyl-D-aspartate receptor antibody encephalitis in 2019; addition of ABO incompatible hematopoietic progenitor cell transplantation and ANCA-associated vasculitis in 2010; other incremental changes in 2017, 2015, 2013, and 2008).